Biomarker · Gene alteration

BCR-ABL1 fusion (Philadelphia chromosome)

The BCR-ABL1 fusion from t(9;22) detected by karyotype, FISH or quantitative RT-PCR of blood or marrow; the defining diagnostic marker of chronic myeloid leukemia, a predictive marker for ABL tyrosine kinase inhibitors, and a molecular-response marker.

CI-BIO-00000052ABL1 graph →BCR graph →NCIt C94600

Also calledBCR-ABL1 · BCR::ABL1 · Philadelphia chromosome · Ph+ · t(9;22) · p210 · p190

Derived

Associated cancers (6)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Chronic Myeloid Leukemia, BCR-ABL1 Positive	297	293	—	4	4 / 26 / 146 / 121 / 0
Malignant Neoplasm	22	22	—	—	0 / 0 / 0 / 22 / 0
Acute Lymphoblastic Leukemia	6	6	—	—	0 / 0 / 4 / 2 / 0
B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1	4	—	—	4	0 / 4 / 0 / 0 / 0

Derived

Drugs with predictive evidence (8)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
DasatinibSmall Molecule	106	14	92	A	9 / 47	Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Malignant Neoplasm
Imatinib MesylateSmall Molecule	67	—	67	B

Curated evidence

Predictive evidence items (323)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 323 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 T315I + ABL1 Fusion5
Axitinib +

Regulatory

Approvals mentioning the linked drugs (209)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

ema

Clinical trials

Active trials (39)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 19 recruiting · 5 active phase 3 · 223 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–39 of 39 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07269470	Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase	recruiting	Phase 2

Literature

Linked publications (32)

Publications linked to the scope variant(s) through PubMed entity edges; 25 per page, newest first.

pubmedPublishedShowing 1–25 of 32 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
· Oncogene · 2002 · PMID 12476305 · validated civic_curation pubmed
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
· Leuk Res · 2010 · PMID 20537386 · validated civic_curation pubmed
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
· Blood · 2008 · PMID 18818391 · validated civic_curation pubmed
Resistant mutations in CML and Ph(+)ALL - role of ponatinib.
· Biologics · 2014 · PMID 25349473 · validated

ABL1 Fusion3
Dasatinib	Acute Lymphoblastic Leukemia	Predictive	C	Supports Sensitivity Response	3	accepted	EID4436 Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with no secondary variants in at least ten bacterial clones generated using perip… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
Imatinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID259 Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID232 BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC	civic

ABL1 E255K + ABL1 Fusion2
Dasatinib	Acute Lymphoblastic Leukemia	Predictive	C	Supports Resistance	3	accepted	EID4718 Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with the E255K secondary variant in 3/12 bacterial clones generated using periphe… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID4355 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed increased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic

ABL1 Y253H + ABL1 Fusion3
Dasatinib	Acute Lymphoblastic Leukemia	Predictive	C	Does Not Support Resistance	3	accepted	EID7947 Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with Y253H and Y253H/Q252R variants in 9/10 and 1/10 clones, respectively. Clones… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID4329 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID4330 In an in vitro study, pro-B Ba/F3 cell line expressing Y253H mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 1069.7nM)… (full text at CIViC) PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC	civic

ABL1 F359V + ABL1 Fusion3
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID3822 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	2	accepted	EID3815 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	1	accepted	EID3816 This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC) PMID 22371878 · Khoury et al., 2012 · Open in CIViC	civic

ABL1 L248V + ABL1 Fusion2
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID4311 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed decreased incorporation when harboring fusions with t… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	2	accepted	EID4310 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Asciminib	EU EMA	Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive	Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP). Scemblix is indicated for the treatment of adult patients with Ph+ CML-CP with the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib (see section 5.1).	approved	Aug 25, 2022	ema
Asciminib	US FDA	—	SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). Previously treated Ph+ CML in CP. Ph+ CML in CP with the T315I mutation. SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) Previously treated Ph+ CML in CP. ( 1 ) Ph+ CML in CP with the T315I mutation. ( 1 )accelerated	approved	Oct 29, 2021	openfda
Asciminib	US FDA	—	SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). Previously treated Ph+ CML in CP. Ph+ CML in CP with the T315I mutation. SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) Previously treated Ph+ CML in CP. ( 1 ) Ph+ CML in CP with the T315I mutation. ( 1 )accelerated	approved	Oct 29, 2021	openfda
Axitinib	CA Health Canada	—	Marketed in Canada as INLYTA (DIN 02389630) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 17, 2012	health-canada-dpd
Axitinib	CA Health Canada	—	Marketed in Canada as INLYTA (DIN 02389649) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 17, 2012	health-canada-dpd
Axitinib	CA Health Canada	—	Marketed in Canada as INLYTA (DIN 02422891) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025	—	health-canada-dpd
Axitinib	CA Health Canada	—	Marketed in Canada as INLYTA (DIN 02422883) under ATC L01EK01 AXITINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025	—	health-canada-dpd
Axitinib	EU EMA	Renal Cell Carcinoma	Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.	approved	Sep 19, 2024	ema
Axitinib	EU EMA	Renal Cell Carcinoma	Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.	approved	Sep 3, 2012	ema
Axitinib	US FDA	—	Efficacy supplement 2022-09-22 (see label)	approved	Sep 22, 2022	openfda
Axitinib	US FDA	—	Efficacy supplement 2020-06-04 (see label)	approved	Jun 4, 2020	openfda
Axitinib	US FDA	—	in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC.	approved	Jan 27, 2012	openfda
Axitinib	US FDA	Renal Cell Carcinoma	in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC).	approved	Jan 27, 2012	openfda
Axitinib	US FDA	Renal Cell Carcinoma	as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.	approved	Jan 27, 2012	openfda
Blinatumomab	EU EMA	Acute Lymphoblastic Leukemia	Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19 positive B‑cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with high-risk first relapsed Philadelphia chromosome-negative CD19 positive B-cell precursor ALL as part of the consolidation therapy (see section 4.2). Blincyto is indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome negative CD19 positive B-cell precursor ALL.	approved	Nov 23, 2015	ema
Bosutinib	CA Health Canada	—	Marketed in Canada as REDDY-BOSUTINIB (DIN 02560046) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 8, 2025	health-canada-dpd
Bosutinib	CA Health Canada	—	Marketed in Canada as REDDY-BOSUTINIB (DIN 02560038) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 8, 2025	health-canada-dpd
Bosutinib	CA Health Canada	—	Marketed in Canada as BOSULIF (DIN 02419149) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 24, 2014	health-canada-dpd
Bosutinib	CA Health Canada	—	Marketed in Canada as BOSULIF (DIN 02419157) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 24, 2014	health-canada-dpd
Bosutinib	CA Health Canada	—	Marketed in Canada as REDDY-BOSUTINIB (DIN 02560011) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved	—	health-canada-dpd
Bosutinib	CA Health Canada	—	Marketed in Canada as BOSULIF (DIN 02483793) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Pre Marketsince Mar 31, 2025	—	health-canada-dpd
Bosutinib	EU EMA	Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive	Bosulif is indicated for the treatment of:• Adult and paediatric patients aged 6 years and older with newly-diagnosed (ND) chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).• Adult and paediatric patients aged 6 years and older with CP Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.• Adult patients with accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.	approved	Mar 27, 2013	ema
Bosutinib	US FDA	Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive	adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 )	approved	Sep 26, 2023	openfda
Bosutinib	US FDA	—	Efficacy supplement 2023-09-26 (see label)	approved	Sep 26, 2023	openfda
Bosutinib	US FDA	—	Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )	approved	Sep 26, 2023	openfda
Bosutinib	US FDA	—	Efficacy supplement 2021-05-14 (see label)	approved	May 14, 2021	openfda
Bosutinib	US FDA	—	Efficacy supplement 2017-12-19 (see label)	approved	Dec 19, 2017	openfda
Bosutinib	US FDA	—	Efficacy supplement 2017-04-13 (see label)	approved	Apr 13, 2017	openfda
Bosutinib	US FDA	—	Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] . BOSULIF is a kinase inhibitor indicated for the treatment of • adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. ( 1 )	approved	Sep 4, 2012	openfda
Bosutinib	US FDA	Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive	adult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy. ( 1 )	approved	Sep 4, 2012	openfda
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562502) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562464) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562480) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562472) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB TABLETS (DIN 02562499) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 31, 2026	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478315) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478323) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478358) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478331) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TEVA-DASATINIB (DIN 02478307) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	May 5, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499320) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499339) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499282) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499304) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499312) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as TARO-DASATINIB (DIN 02499347) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 4, 2021	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02481499) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02470705) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02470713) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd
Dasatinib	CA Health Canada	—	Marketed in Canada as APO-DASATINIB (DIN 02470721) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 6, 2020	health-canada-dpd